Evidence map›Paper›PMID 32350565›Full record

ArticleDiabetologia2020

Inhibition of the prostaglandin D

Shadab Abadpour, Björn Tyrberg, Simen W Schive, Charlotte Wennberg Huldt, Peter Gennemark, Erik Ryberg, Tina Rydén-Bergsten, David M Smith, Olle Korsgren, Stanko Skrtic and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetologia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.7field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. One-Step Automatic Radiosynthesis and Evaluation of [Pharmaceuticals (Basel, Switzerland) · 2023
    Article
  3. Article
  4. [Pharmaceutics · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Shadab AbadpourDepartment of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway.
Björn TyrbergResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Simen W SchiveDepartment of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway.
Charlotte Wennberg HuldtResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Peter GennemarkResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Erik RybergResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Tina Rydén-BergstenResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
David M SmithResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Olle KorsgrenDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, University of Uppsala, Uppsala, Sweden.
Stanko SkrticResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden.
Hanne ScholzDepartment of Transplant Medicine and Institute for Surgical Research, Oslo University Hospital, Sognsvannsveien 20, 0027, Oslo, Norway. hanne.scholz@medisin.uio.no.
Maria Sörhede WinzellResearch and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Peppredsleden 1, 431 83 Mölndal, Gothenburg, Sweden. maria.sorhede-winzell@astrazeneca.com.
AstraZeneca (Sweden) · SEOslo University Hospital · NOAstraZeneca (United Kingdom) · GBLinköping University · SEScience for Life Laboratory · SEUniversity of Oslo · NO

Funding

Research Council of Norway - Center of Excellence 262613South Eastern Norway Regional Health Authority 2012031
6 · The paper itself

Abstract

aims/hypothesisInflammatory signals and increased prostaglandin synthesis play a role during the development of diabetes. The prostaglandin D

methodsHuman islets were exposed to PGD

resultsPGD CONCLUSIONS/

interpretationInhibition of GPR44 in human islets has the potential to improve islet function and survival rate under inflammatory and hyperglycaemic stress. This may have implications for better survival rate of islets following transplantation.

Indexed as

ApoptosisBlotting, WesternCell DeathDNA-Binding ProteinsGlucoseHumansInsulinInsulin SecretionIslets of LangerhansProstaglandin D2Real-Time Polymerase Chain ReactionReceptors, ImmunologicReceptors, ProstaglandinTranscription FactorsDNA-Binding ProteinsGlucoseInsulinProstaglandin D2prostaglandin D2 receptorReceptors, ImmunologicReceptors, ProstaglandinTFDP2 protein, humanTranscription FactorsDP2GPR44Human isletsIslet apoptosisIslet survival rateProstaglandin D2

Identifiers

PMID32350565
PMCPMC7286861
OpenAlexW3021743770

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.